Early development gene therapy
Early development gene therapy
NavIntus was formed in 2021 to advance groundbreaking DNA-based drug delivery research in the management of chronic pain. Incorporating a “Trojan Horse” platform, this novel non-viral gene therapy delivery will target the Nav 1.7 pathway to offer a non-opioid alternative to chronic moderate-to-severe pain using the patient’s own cells to manufacture the required proteins.
To advance the science of gene therapy in chronic pain for improved quality of life without the risks of dependence and addiction associated with opioids.
For inquiries email james.kerrigan@navintus.com
Monday - Friday: 8:00am - 5:00pm
Saturday - Sunday: Closed
Copyright © 2023 Navintus Inc. - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.